Yonghui Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yonghui Zhang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Jie Li
Laboratory of Biological Psychiatry, Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China
4 shared publications Xiaoli Wang
Laboratory of Biological Psychiatry, Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China
3 shared publicationsHongyu Zhang
Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China
2 shared publicationsJingxuan Liu
Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China
2 shared publicationsMeijuan Li
Laboratory of Biological Psychiatry, Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, 13 Liulin Road, Tianjin, 300222, China
2 shared publicationsQiao Su
Laboratory of Biological Psychiatry, Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, 13 Liulin Road, Tianjin, 300222, China
2 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by Springer Nature in BMC Psychiatry
Association between serum non-enzymatic antioxidants and cognitive impairment in drug-naïve patients with schizophrenia
Cognitive impairment (CI) is a core feature of schizophrenia (SZ) and is strongly associated with poor functional outcomes. Oxidative stress and impaired antioxidant defense are implicated in the pathogenesis of CI across psychiatric disorders. But evidence in drug-naïve SZ remains limited. Serum levels of non-enzymatic antioxidants, including high-density lipoprotein cholesterol (HDL-C), albumin (ALB), total bilirubin (TBIL), and uric acid (UA), were measured in drug-naïve patients with SZ and healthy controls (HCs). Cognitive function was assessed using the MATRICS Consensus Cognitive Battery (MCCB), and psychiatric symptoms using the Positive and Negative Syndrome Scale (PANSS). Multivariable logistic regression models were used to evaluate associations between antioxidants and CI, with interaction and stratified analyses based on demographic and clinical variables. Linear regression analyses were used to evaluate the relationships between antioxidants and specific cognitive domains. A total of 219 drug-naïve patients with SZ and 101 HCs were included. CI was identified in 115 SZ patients (52.5%). Serum levels of HDL-C (p = 0.004) and ALB (p = 0.001) were significantly lower in patients with SZ than in HCs, whereas UA (p = 0.001) was higher. Within the SZ group, patients with CI showed lower levels of HDL-C (p = 0.019) and ALB (p = 0.033) compared with those without CI. Logistic regression analyses showed that higher HDL-C (OR:0.30, 95% CI: 0.11-0.82) and ALB (OR:0.91, 95% CI: 0.84-0.99) levels were independently associated with lower odds of CI. In addition, linear regression analyses revealed that HDL-C (p = 0.025) and ALB (p = 0.008) were positively associated with overall cognitive performance, and ALB was also associated with verbal learning (q = 0.007). This study suggests that higher serum HDL-C and ALB levels are associated with lower odds of CI and better overall cognitive performance in drug-naïve patients with SZ.
- 10 June 2026
- Published by Springer Nature in BMC Psychiatry
Open AccessAssociation between serum non-enzymatic antioxidants and cognitive impairment in drug-naïve patients with schizophrenia
Cognitive impairment (CI) is a core feature of schizophrenia (SZ) and is strongly associated with poor functional outcomes. Oxidative stress and impaired antioxidant defense are implicated in the pathogenesis of CI across psychiatric disorders. But evidence in drug-naïve SZ remains limited. Serum levels of non-enzymatic antioxidants, including high-density lipoprotein cholesterol (HDL-C), albumin (ALB), total bilirubin (TBIL), and uric acid (UA), were measured in drug-naïve patients with SZ and healthy controls (HCs). Cognitive function was assessed using the MATRICS Consensus Cognitive Battery (MCCB), and psychiatric symptoms using the Positive and Negative Syndrome Scale (PANSS). Multivariable logistic regression models were used to evaluate associations between antioxidants and CI, with interaction and stratified analyses based on demographic and clinical variables. Linear regression analyses were used to evaluate the relationships between antioxidants and specific cognitive domains. A total of 219 drug-naïve patients with SZ and 101 HCs were included. CI was identified in 115 SZ patients (52.5%). Serum levels of HDL-C (p = 0.004) and ALB (p = 0.001) were significantly lower in patients with SZ than in HCs, whereas UA (p = 0.001) was higher. Within the SZ group, patients with CI showed lower levels of HDL-C (p = 0.019) and ALB (p = 0.033) compared with those without CI. Logistic regression analyses showed that higher HDL-C (OR:0.30, 95% CI: 0.11-0.82) and ALB (OR:0.91, 95% CI: 0.84-0.99) levels were independently associated with lower odds of CI. In addition, linear regression analyses revealed that HDL-C (p = 0.025) and ALB (p = 0.008) were positively associated with overall cognitive performance, and ALB was also associated with verbal learning (q = 0.007). This study suggests that higher serum HDL-C and ALB levels are associated with lower odds of CI and better overall cognitive performance in drug-naïve patients with SZ.
- Open Access
- 20 February 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Diagnosis-specific associations of plasma NGAL in drug-naïve schizophrenia and major depressive disorder: an exploratory cross-sectional study
Schizophrenia (SCZ) and major depressive disorder (MDD) share overlapping clinical features. We examined plasma neutrophil gelatinase-associated lipocalin
- 20 February 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessDiagnosis-specific associations of plasma NGAL in drug-naïve schizophrenia and major depressive disorder: an exploratory cross-sectional study
Schizophrenia (SCZ) and major depressive disorder (MDD) share overlapping clinical features. We examined plasma neutrophil gelatinase-associated lipocalin
- Open Access
- 22 December 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Prevalence and correlates of overweight and obesity in patients with major depression accompanied by abnormal TSH levels
Abnormal thyroid function is common in patients with major depressive disorder (MDD), which may be closely associated with metabolic disturbances, especial
- 22 December 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessPrevalence and correlates of overweight and obesity in patients with major depression accompanied by abnormal TSH levels
Abnormal thyroid function is common in patients with major depressive disorder (MDD), which may be closely associated with metabolic disturbances, especial
- 24 November 2025
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (6) , 1-8
Smoking and its associations with metabolic indices, clinical symptoms, and cognitive functioning in schizophrenia
- 24 November 2025
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (6) , 1-8
Smoking and its associations with metabolic indices, clinical symptoms, and cognitive functioning in schizophrenia